Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms More
Methods, systems and transgenic animals useful for screening, diagnosing and treating FUS1 related disorders More
Novel compositions and methods for delivering inhibitory oligonucleotides to cells in a targeted and efficient manner have been developed. More
MGD3 monoclonal antibody binds human Dectin-1 with high affinity and regulates production of cytokines TNF-α and Interleukin-10. MGD3 has a potential therapeutic use on inflammatory diseases. More
immuno-suppresant agent More
Novel agents that can interfere with the action of nuclear hormone receptors More
Compositions and methods for targeted therapeutic release of encapsulated materials from multi functional liposomes at the site of a solid tumor or a diseased site using ionizing and non-ionizing radiation, a process called conformal Intensity Modulated R More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
A novel fusion protein capable of binding to any internalizing IgG, thus forming a specific and potent immunotoxin, has been developed. The antibody-toxin conjugate is formed through an immuno-complex and may be further stabilized by chemical... More
Related Reports
Market Research Reports provided by reports.innovaro.com
May 2011 - 15 pages - $250
Dec 2010 - 37 pages - $500
Jan 2010 - $75
Jan 2011 - 34 pages - $500
Nov 2010 - 40 pages - $500
May 2011 - 15 pages - $250
Apr 2011 - 75 pages - $3,800
Dec 2010 - 22 pages - $500
Oct 2011 - 113 pages - $2,795
Jul 2011 - 136 pages - $500
Your selection
- Therapeutic target
- Immune related disorders del
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us